Companies · Biotech
DOVER · CA, USA; Remote · Biotech · refined from filed group “Other Technology” · founded 2022 · http://www.invertbio.com/
Diligence memoA one-page analyst read on Invert, Inc. — recommendation, valuation, rhythm, risks.→Invert, Inc. looks fair against its niche peers and is at-risk on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Invert, Inc. is one of 233 Biotech companies tracked from DOVER, CA, USA; Remote, on record since 2022. By capital raised it ranks among the largest (ahead of 90% of sector peers), and among the largest by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
Data analytics software for biomanufacturing.
We build software to manage, analyze, and optimize bioprocessing data. Our initial customers are bio-industrial companies, who produce various products in bioreactors.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 25%.
Round size and date are reported; the stage label is inferred from round size (latest is Series B — a $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 233 companies in Biotech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 90% of sector peers (real $). Modeled value above 91% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #5 of 7.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Watchmaker Genomics, Inc. | Series B | $48.3M | $713.6M | 4.62× |
| Mytos, Inc. | Series B | $18.0M | $179.5M | 1.16× |
| ZBiotics Co | Series B | $28.1M | $179.3M | 1.16× |
| Siren Biotechnology, Inc. | Series B | $19.6M | $154.4M | 1.00× |
| Invert, Inc. this company | Series B | $20.1M | $144.8M | 0.94× |
| AgNovos Bioscience, Inc. | Series B | $44.8M | $119.9M | 0.78× |
| Volta Labs, Inc. | Series B | $37.7M | $112.4M | 0.73× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Series B | $20.1M | 2024-06-25 | $111.9M | $144.8M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Christian Hjorth Tang-Jespersen | — | — | 2024-06 |
| Holger Hjorth Thorup | — | — | 2024-06 |
| Martin Tromp Permin | — | — | 2024-06 |
| Sam Hjorth Cates | — | — | 2024-06 |
Invert, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| hC Bioscience, Inc. | Biotech | Series B | $20.0M | $431.1M | same sector · same stage |
| Siren Biotechnology, Inc. | Biotech | Series B | $19.6M | $154.4M | same sector · same stage |
| Mytos, Inc. | Biotech | Series B | $18.0M | $179.5M | same sector · same stage |
| Phylos Bioscience, Inc. | Biotech | Series B | $23.9M | $2.2M | same sector · same stage |
| Yield10 Bioscience, Inc. | Biotech | Series B | $27.3M | $90.6M | same sector · same stage |
| ZBiotics Co | Biotech | Series B | $28.1M | $179.3M | same sector · same stage |
| Goodwin Biotechnology, Inc | Biotech | Series B | $30.7M | $7.7M | same sector · same stage |
| Debut Biotechnology, Inc. | Biotech | Series B | $31.5M | $88.8M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Invert Industries | Manufacturing / Industrial | Pre-Seed | $1.2M | 79% |
| INVO Bioscience, Inc. | Biotech | Seed | $29.2M | 78% |
| Invent Analytics Inc. | Software / Tech | Series B | $135.7M | 76% |
| AminoAnalytica The AI scientist for always-on biodefense | Biotech | — | — | 76% |
| Sistema.bio, Inc. | Biotech / Pharma | Series A | $21.5M | 76% |
| Epoch Biotech, LLC | Biotech | Pre-Seed | $797K | 76% |
| Scispot The Best Data Infrastructure for Biotechs | Biotech | — | — | 76% |
| INIA Biosciences, Inc. | Biotech / Pharma | Pre-Seed | $1.3M | 76% |
See where Invert, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Invert, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.